1

Iovance Biotherapeutics

#6014

Rank

$1B

Marketcap

US United States

Country

Iovance Biotherapeutics
Leadership team

Dr. Frederick G. Vogt Esq., J.D., Ph.D. (Interim CEO, Pres, Gen. Counsel & Corp. Sec.)

Mr. Jean-Marc Bellemin M.B.A. (Chief Financial Officer & Principal Accounting Officer)

Dr. Igor P. Bilinsky (Chief Operating Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2007
Company Registration
SEC CIK number: 0001425205
Traded as
IOVA
Social Media
Overview
Location
Summary
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma ?nd became lion bio Pharma, then rebranded to Iovance in 2017.

Mission
At Iovance, our mission is to develop and deliver life-changing T cell-based immunotherapies to people with cancer.
Vision
We envision a world where cancer is addressed through safe and effective immunotherapies for people regardless of their age, gender, socioeconomic background or geographic location.
Key Team

Ms. Sara Pellegrino (VP of Investor Relations & PR)

Ms. Tracy Winton (Sr. VP of HR)

Mr. James Ziegler M.B.A. (Exec. VP of Commercial)

Mr. Howard B. Johnson M.B.A. (Chief Bus. Officer)

Mr. Madan Jagasia (Exec. VP of Medical Affairs)

Dr. Raj K. Puri M.D., Ph.D. (Exec. VP of Regulatory Strategy & Translational Medicine)

Dr. Friedrich Graf Finckenstein M.D. (Chief Medical Officer)

Recognition and Awards
Iovance Biotherapeutics won the Breakthrough Therapy designation in 2020 for its TIL therapy product candidate, lifileucel, in unresectable and/or metastatic melanoma.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Iovance Biotherapeutics
Leadership team

Dr. Frederick G. Vogt Esq., J.D., Ph.D. (Interim CEO, Pres, Gen. Counsel & Corp. Sec.)

Mr. Jean-Marc Bellemin M.B.A. (Chief Financial Officer & Principal Accounting Officer)

Dr. Igor P. Bilinsky (Chief Operating Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2007
Company Registration
SEC CIK number: 0001425205
Traded as
IOVA
Social Media